News

March 26th, 2014
Xenon and Genentech Establish New Pain Discovery Collaboration
Vancouver, Canada (March 26, 2014) – Xenon Pharmaceuticals Inc. today announced the establishment of a new collaboration with Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX:... read more >

September 10th, 2013
Xenon Announces Appointment of Ian C. Mortimer as Chief Financial Officer
Vancouver, Canada (September 10th, 2013) – Xenon Pharmaceuticals Inc. is pleased to announce the appointment of Mr. Ian C. Mortimer as Chief Financial Officer. “We are delighted to welcome... read more >

June 10th, 2013
Xenon Licenses Antisense Drug XEN701 from Isis and Initiates Preclinical Toxicology Studies
Carlsbad, Calif. and Vancouver, Canada, (June 10, 2013) – Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) and Xenon Pharmaceuticals Inc. announced today that Xenon has exercised its option to an exclusive... read more >

April 23rd, 2013
Teva and Xenon Announce FDA Orphan Drug Designation for Pain Drug XEN402
Jerusalem, Israel, and Burnaby, British Columbia, (April 23, 2013) – Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) and Xenon Pharmaceuticals Inc. (Xenon) announced today that the US Food and Drug... read more >